Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line
Human Cell · 2024
DOI: 10.1007/s13577-024-01077-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Prin Sungwan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate, School of Medical Sciences, Kumamoto University, 2-2-1 Ho…. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Ministry of Economy, Trade and Industry.
Abstract (Originalsprache)
TK-ALCL1, a novel anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALK+ ALCL) cell line, was established from the primary tumor site of a 59-year-old Japanese male patient. The immune profile of TK-ALCL1 corresponds to that seen typically in primary ALCL cells, i.e., positive for ALK, CD30, EMA, and CD4, but negative for CD2, CD3, CD5, CD8a, and EBV-related antigens. The rearrangement of the T cell receptor-gamma locus shows that TK-ALCL1 is clonally derived from T-lineage lymphoid cells. FISH and RT-PCR analysis revealed that TK-ALCL1 has the nucleophosmin (NPM)-ALK fusion transcript, which is typical for ALK+ ALCL cell lines. When TK-ALCL1 was subcutaneously inoculated into 6-week-old BALB/c Rag2-/-/Jak3-/- (BRJ) mice, it formed tumor masses within 4-6 weeks. Morphological, immunohistochemical, and molecular genetic investigations confirmed that the xenograft and the original ALCL tumor were identical. The ALK inhibitors Alectinib and Lorlatinib suppressed proliferation in a dose-dependent manner. Thus, TK-ALCL1 provides a useful in vitro and in vivo model for investigation of the biology of ALK+ ALCL and of novel therapeutic approaches targeting ALK.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate, School of Medical Sciences, Kumamoto University, 2-2-1 Honjo, Chuou-ku, Kumamoto, 860-0811, Japan.
- Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.
- Institute of Industrial Nanomaterials, Kumamoto University, 2-39-1 Kurokami, Chuou-ku, Kumamoto, 860-8555, Japan.
- Division of Musculoskeletal Oncology and Orthopaedics Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
- Clinical Laboratory Center, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
- Division of Diagnostic Pathology, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
Förderung
- Ministry of Economy, Trade and Industry
Zitieren
APA
Sungwan, P., Panaampon, J., Kariya, R., Kamio, S., Nakagawa, R., Hirozane, T., Ogura, Y., Abe, M., Hirabayashi, K., Fujiwara, Y., Kikuta, K., & Okada, S. (2024). Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line. Human Cell. https://doi.org/10.1007/s13577-024-01077-8
Vancouver
Sungwan P, Panaampon J, Kariya R, Kamio S, Nakagawa R, Hirozane T, et al. Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line. Human Cell. 2024. doi:10.1007/s13577-024-01077-8
BibTeX
@article{Sungwan2024,
author = {Sungwan, Prin and Panaampon, Jutatip and Kariya, Ryusho and Kamio, Satoshi and Nakagawa, Rumi and Hirozane, Toru and Ogura, Yukiko and Abe, Makoto and Hirabayashi, Kaoru and Fujiwara, Yukio and Kikuta, Kazutaka and Okada, Seiji},
title = {Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line},
journal = {Human Cell},
year = {2024},
doi = {10.1007/s13577-024-01077-8}
}
EUVIMED